Pioneer in AI+ICU: Maicim Launches Clinical Intelligent Decision Support System to Empower Physicians
Some people say,ICU, is a department soaked in tears. It is cold and heavy; patients are covered with various instruments or catheters, fighting for the hope of survival against death every second.
ICUIntensive Care Unit (ICU)ICUHaving spanned nearly half a century, our countryICUThe establishment can be traced back to the last century.80In the early years. Currently, hospitals at Level II and above in China are required to be equipped with intensive care units.
“InICU, massive amounts of data are generated every day. However, most of this data is not well organized or utilized. Our clinical intelligent decision support system can monitor and collect these data, and then, based on ourAI"The algorithm analyzes this data to assist physicians in clinical decision-making." — MaiXing MedicalCEOHuang Kezhi said.
Maixing Medical isChina's First Specialist in Intensive Care (ICU) Big DataAIenterprises. Amid the sweeping tide of healthcare informatization, few companies have applied artificial intelligence technology toICUIn the ward, Maixing Medical has independently developed two majorAI+ICUFlagship product, becoming a "pioneer" in this field.
From September 19 to 22, 2019, the Chinese Critical Care Congress (CCCC2019) was held in Wuhan. Experts and colleagues from the field of critical care medicine, both domestic and international, gathered together to deliver insightful academic presentations on the latest clinical advances and hot topics, research directions, and management models.
At this conference, from Imperial College LondonAnthony GordonThe professor shared insights on artificial intelligence technology inICUapplications. Meanwhile, Maixing Medical is the only company that applies artificial intelligence toICUcompanies in the field, newly launchedAI+ICUIntelligent Clinical Decision Support Systems Have Drawn Close Attention from Many Expert Physicians.
During the conference, Professor Du Bin, Director of the Medical Intensive Care Unit (MICU) at Peking Union Medical College Hospital; Yan Jing, Party Secretary of Zhejiang Hospital; Professor Weng Li, Deputy Director of the MICU at Peking Union Medical College Hospital; Director Wu Guobao of The Second Xiangya Hospital; and other distinguished guests visited the booth of Maixing Medical. They highly affirmed its products and provided relevant guidance.
At the exhibition, Maixing also attracted significant attention from ICU directors at primary-care hospitals. Given the severe shortage of medical resources and the uneven quality of care in these settings, many directors expressed that artificial intelligence has broad application prospects in ICUs. They hope to adopt Maixing’s AI-powered clinical decision support system as soon as possible to enhance capabilities in clinical diagnosis and treatment, management, scientific research, and quality control.
Figure Caption:Professor Du Bin (third from left), Conference Chair, and Professor Ma Penglin (second from left) visited the Maixing booth for guidance.
How Can Artificial Intelligence Technology Be Deeply Integrated with Clinical Scenarios? And How Does Maixing Achieve This ThroughAIHow does the platform assist physicians in clinical decision-making? After the conference, VCBeat had the privilege of interviewing MaiXing Medical.CEOHuang Kezhi and Chen Weiren, Medical Director, provided a detailed interpretation of the above issues.
>>>>
Behind the ICU’s “Gate of Life and Death”: High Incidence of Medical Errors and Massive Patient Data
ICUIt is a “gate of life and death” standing between patients and their families. Sending inICUpatients are classified into three types: 1. viaICUTreatment for patients with acute, reversible, life-threatening organ dysfunction who can recover in the short term.
II. JingICUClose monitoring and treatment may reduce the risk of death in patients with potentially life-threatening conditions. 3. Acute exacerbations and life-threatening conditions have occurred, as evidenced byICUActively treat patients with chronic organ dysfunction who may recover to their baseline status.
Simply put, enteringICUpatients are basically "facing a grim prognosis." Against this backdrop,Every fluctuation in a patient’s data and every cautious medication administration by healthcare professionals can play a decisive role in sustaining life.
According to Yubo Zhiye's “ICU"Industry Market Research and Analysis Report," the United States2005YearICUThe error rate is as high as1497time/Per 10,000 people, of which those posing a serious threat to life account for13%; average daily incidence per person1.7medical errors, with an annual average of9.810,000ICUThe patient died due to a medical error.Among these medical errors,28%～84% All are preventable, it is just that hospitals need to find an effective way to address this issue.
High Incidence of Medical Errors Has BecomeICUan important attribute. Furthermore, inICU, the instruments used on patients to monitor treatment can generate large amounts of data every day. However, the detected data streams are not collected; alerts are only triggered in cases of specific abnormalities.
Given the high potential risks of errors and the large volume of patient data, achieving real-time and effective monitoring is particularly crucial.
So, how can we reduce error rates without imposing a heavy workload on healthcare professionals? Maixing MedicalCEOHuang Kezhi told VCBeat,AIEffectively addressing these pain points.
Becoming the “Eyes” of Doctors: Maijianxing’s Clinical Intelligent Decision Support System and AI Research Platform
Currently, artificial intelligence applications in the healthcare sector are mostly superficial. Maixing Medical leveragesAI"Technology's entry into critical healthcare scenarios can be described as an innovative approach."
2016In [year], Maixing Medical was established. In just a short3Years, Maixing MedicalBuiltAIResearch Platform,AI+ICUIntelligent Decision Support System, with technical capabilities reaching or even surpassing those of developed countries.
Amid the booming startup frenzy in medical AI, due to the high industry entry barriers,ICUThe market has kept many companies at bay. The reason Maixing Medical dares to delve deeply into this market lies in Maixing Medical’sCEOAccording to Huang Kezhi, the reason lies in the strong “technical DNA” possessed by the company’s core team members:Proportion of R&D Personnel in the Overall Team Composition80%, with over % holding master's or doctoral degrees50%。
Figure Legend:Maixing MedicalCEOHuang Kezhi
“Our team comprises medical AI scientists, clinicians, algorithm specialists, and healthcare informatics experts, laying the foundation for us to develop products that truly align with clinical needs.” – MaiXing MedicalCEOHuang Kezhi introduced.
AI+ICUThe Intelligent Clinical Decision Support System is a platform that integrates three leading technologies: “Natural Language Processing, Knowledge Graphs, and Machine Learning.”AIIntelligent Platform of Technology.
The core of the product is real-time display of personalized dynamic clinical data,AIMortality Prediction and Disease Risk Prediction: Unlocking the Value of Clinical Data to Build a Fully Closed-Loop Intelligent Ecosystem for Enhanced ServicesICUThe Purpose of Healthcare Professionals' Decision-Making.
Figure legend:Maixing Clinical Knowledge System Architecture
"InICUIn the ward, many diseases remain undiagnosed, particularly certain secondary complications. Once they occur, patients face life-threatening risks. OurProductachieved prior to the occurrence of24provide early warnings hours or even earlier and assist physicians in formulating management plans, advising them on appropriate actions before an event occurs,Currently, the clinical data validation accuracy of the mortality prediction model developed by Maixing exceeds90%。“Chen Weiren, Medical Director at Maixing Medical, told VCBeat.”
InAI+ICUIn the intelligent clinical decision support system, two representative technological products are featured: the Intelligent Respiratory Therapy Management Platform and the Acute Kidney Injury Prediction System.
The Intelligent Respiratory Therapy Management Platform is a collaboration between Maixing and Peking Union Medical College HospitalMICUJointly developed near2Year, using Peking Union Medical College Hospital5years of real-world clinical data. The first phase involves using machine learning techniques to build predictive models for predicting weaning success rates,Currently deployed and in use at Peking Union Medical College Hospital for nearly9months, with a prediction success rate of90%Above。
The R&D focus of the second phase is to construct a ventilator knowledge graph that maps onto machine learning models, thereby addressing the lack of interpretability inherent in machine learning. Meanwhile, the knowledge graph will enable intelligent interactive question-and-answer sessions with physicians and perform proactive reasoning to generate standardized treatment plans based on evidence-based medicine.
Intelligent Management Platform for Respiratory Therapy and Acute Kidney Injury Prediction Enable Early Intervention Through Real-Time Data Collection,It can promptly prevent the deterioration of patients' conditions, reduce related complications, lower medical expenses for patients, and improve patient prognosis.
Chen Weiren, Medical Director at Maixing Medical, stated that in addition to addressing the aforementioned issues, another prominent feature of the system is its ability to support clinical research.
Figure Legend:Core Value of VCBeat Products
“Leveraging our powerful algorithms, we willICU“Data from various devices and information systems within the department have been integrated, and undergone structured and standardized processing,” said Chen Weiren, Medical Director at Maixing Medical.
CombinedAI+ICUData Output by the Intelligent Clinical Decision Support System for Physician ServicesAIResearch platforms have thus emerged. The two are mutually reinforcing, jointly maximizing data utilization.
The product demonstrates significant efficacy:For physicians: enhancing diagnostic and treatment capabilities, reducing clinical error rates, enabling early warning for timely intervention, prioritizing prevention over treatment, minimizing medical disputes, and advancing research proficiency.
For patients, it reduces medical costs, improves prognostic outcomes, prevents overtreatment, and avoids diagnostic and therapeutic errors. For the market, it fills the gap in clinical decision support systems for critical care, empowering clinicians and hospitals to enhance their research and clinical capabilities.
Currently, Maixing Medical has established collaborations with hospitals such as Peking Union Medical College Hospital, Zhejiang Hospital, the Second Xiangya Hospital, and the First Affiliated Hospital of Zhejiang University School of Medicine, achieving clinical implementation of its products.
VBMedCEOHuang Kezhi introduced that, benchmarking against foreign countries, currently inICUFieldAIProduct R&D has achieved outstanding results, with the United States being a representative example.Medical inforatics corpMedical Software Company, IsraelClew MedicalCompany, United StatesEXCELcompanies and other enterprises, among whichEXCELDeveloped by the CompanyAIProducts Predicting Mortality Have GainedFDAapproved, and in the past two years, these companies have all secured substantial financing.
“As can be seen above,AI+ICUThe market prospects are substantial, and we look forward to the integration of artificial intelligence.ICUdevelopment, future products can achieve the leap from assisted decision-making to replacing decision-making, better serving doctors and patients. Meanwhile, Maixing in other medicalAIThere are also relevant studies in this field,The intelligent prediction model for high-risk pregnant women, developed in collaboration with the Women's Hospital School of Medicine Zhejiang University, can screen for high-risk pregnancies with an accuracy rate exceeding 90%, laying a solid foundation for subsequent clinical applications!“Maixing MedicalCEOHuang Kezhi stated emphatically.
He stated,The next step will be to increase R&D efforts and promote products inICUDownstream applications in the field are being gradually implemented.AIDevelopment in Other Medical Scenarios.